Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Company Overview

Lisata Therapeutics, Inc. (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies. To advance its programs, the company collaborates with academic institutions and contract research organizations, supporting clinical studies and translational research efforts in North America and Europe.

Headquartered in the United States, Lisata Therapeutics is governed by a leadership team with experience in biotechnology research, clinical operations and regulatory affairs. The company’s board and scientific advisors bring expertise in immunology, drug development and commercial strategy to support its mission of addressing unmet medical needs.

Key Stats

• Today's Range: $3.30 to $3.44
• 50-Day Range: $3.08 to $3.61
• 52-Week Range: $1.81 to $5.07
• Volume: 9,269 shs
• Average Volume: 71,601 shs
• Market Capitalization: $30.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Reduce

Lisata Therapeutics Stock Analysis - MarketRank™

Lisata Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 503rd out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Reduce

Consensus Rating

Lisata Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Lisata Therapeutics has a consensus price target of $15.00, representing about 347.8% upside from its current price of $3.35.

Amount of Analyst Coverage

Lisata Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Lisata Therapeutics has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.09% of the float of Lisata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lisata Therapeutics has a short interest ratio ("days to cover") of 0.45, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lisata Therapeutics has recently decreased by 27.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lisata Therapeutics does not currently pay a dividend.

Dividend Growth

Lisata Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for LSTA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

1 people have added Lisata Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.10% of the stock of Lisata Therapeutics is held by insiders.

Percentage Held by Institutions

8.94% of the stock of Lisata Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 7/06/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LSTA
• CIK: 320017
• Web: www.caladrius.com
• Phone: (908) 842-0100
• Fax: 646-514-7787
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Lisata Therapeutics: $15.00
• High Price Target: $15.00
• Low Price Target: $15.00
• Potential Upside/Downside: +347.8%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.59 million
• Net Margins: N/A
• Pretax Margin: -9,845.88%
• Return on Equity: -103.54%
• Return on Assets: -83.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.23
• Quick Ratio: 4.23

Sales & Book Value

• Annual Sales: $170 thousand
• Price / Sales: 179.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.66 per share
• Price / Book: 2.02

Miscellaneous

• Outstanding Shares: 9,110,000
• Free Float: 8,277,000
• Market Cap: $30.52 million
• Optionable: Not Optionable
• Beta: 0.79